PHARMASSET - 'IFN-Free Oral Option' for HCV - Not a Virgin Territory Anymore!
After the Protease Inhibitors (PIs) wave to treat HCV the race to offer the first “IFN free all oral option” seems to have begun. Preliminary data from Abbott’s PhII trial of IFN-free combination drugs announced last week and data from Boehringer Ingelheim’s IFN-free drugs in upcoming AASLD ’11 is challenging Pharmasset (VRUS) multiprong approach. For more details, please read our report released on Oct. 24th, 2011 on VRUS titled “IFN-free Oral Option” for HCV- Not a Virgin Territory Anymore!
COMPANIES MENTIONED
PHARMASSET
PHARMASSET
